Kezar Life Sciences is a biotechnology business based in the US. Kezar Life Sciences shares (KZR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.85 – an increase of 6.28% over the previous week. Kezar Life Sciences employs 58 staff and has a trailing 12-month revenue of around $7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.85 |
|---|---|
| 52-week range | $0.52 - $1.14 |
| 50-day moving average | $0.62 |
| 200-day moving average | $0.76 |
| Wall St. target price | $2.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.35 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8476 from 2024-10-11
| 1 week (2024-10-07) | 9.51% |
|---|---|
| 1 month (2024-09-13) | 48.70% |
| 3 months (2024-07-12) | 33.08% |
| 6 months (2024-04-12) | -1.75% |
| 1 year (2023-10-13) | -11.39% |
|---|---|
| 2 years (2022-10-14) | -89.85% |
| 3 years (2021-10-14) | 8.77 |
| 5 years (2019-10-14) | 3.27 |
| Revenue TTM | $7 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -28.07% |
| Return on equity TTM | -51.48% |
| Profit margin | 0% |
| Book value | $2.07 |
| Market Capitalization | $58.2 million |
TTM: trailing 12 months
We're not expecting Kezar Life Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Kezar Life Sciences's shares have ranged in value from as little as $0.5202 up to $1.135. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kezar Life Sciences's is 0.211. This would suggest that Kezar Life Sciences's shares are less volatile than average (for this exchange).
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.